Search company, investor...

Metabolic Solutions Development

Founded Year



Debt - II | Alive

Total Raised


Last Raised

$200K | 4 yrs ago

About Metabolic Solutions Development

Metabolic Solutions Development Company (MSDC) is a drug discovery and development company investigating new molecular targets and developing therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes.

Headquarters Location

161 East Michigan Avenue 4th Floor

Kalamazoo, Michigan, 49007,

United States


Missing: Metabolic Solutions Development's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Metabolic Solutions Development's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Metabolic Solutions Development

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Metabolic Solutions Development is included in 2 Expert Collections, including Diabetes.



1,903 items


Biopharma Tech

838 items

Metabolic Solutions Development Patents

Metabolic Solutions Development has filed 13 patents.

patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Rare diseases, Diabetes, Autosomal recessive disorders, Carboxylic acids


Application Date


Grant Date



Related Topics

Transcription factors, Rare diseases, Diabetes, Autosomal recessive disorders, Carboxylic acids



Latest Metabolic Solutions Development News

Metabolic Solutions Development Co. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Dec 1, 2016

Metabolic Solutions Development Co. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 22:46 EST 30 Nov 2016 | BioPortfolio Reports Home » Topics » Biotechnology Business » Latest News » Metabolic Solutions Development Co. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Metabolic Solutions Development Co. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Metabolic Solutions Development Co. since January 2007. Key Findings Provides intelligence on Metabolic Solutions Development Co. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Metabolic Solutions Development Co. and its subsidiaries since 2007. Information about key financial and legal advisors for Metabolic Solutions Development Co.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Metabolic Solutions Development Co.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

Metabolic Solutions Development Frequently Asked Questions (FAQ)

  • When was Metabolic Solutions Development founded?

    Metabolic Solutions Development was founded in 2006.

  • Where is Metabolic Solutions Development's headquarters?

    Metabolic Solutions Development's headquarters is located at 161 East Michigan Avenue, Kalamazoo.

  • What is Metabolic Solutions Development's latest funding round?

    Metabolic Solutions Development's latest funding round is Debt - II.

  • How much did Metabolic Solutions Development raise?

    Metabolic Solutions Development raised a total of $55.9M.

  • Who are the investors of Metabolic Solutions Development?

    Investors of Metabolic Solutions Development include SWMF Life Science Fund, Hopen Life Sciences Ventures and Southwest Michigan Innovation Center.

  • Who are Metabolic Solutions Development's competitors?

    Competitors of Metabolic Solutions Development include Intarcia Therapeutics, Soleno Therapeutics, Cerenis Therapeutics, CymaBay Therapeutics, Intercept Pharmaceuticals and 10 more.

Compare Metabolic Solutions Development to Competitors

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Metabolic Solutions Logo
Metabolic Solutions

Metabolic Solutions is working with a compound in the same class of drugs as two well-known diabetes medications -- Actos and Avandia which combined for sales of more than $5 billion in 2007. The firm says a potential drug Metabolic Solutions is testing now could be safer and more effective than Actos and Avandia.

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

Aderis Pharmaceuticals

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.